News

Bosentan Slows Progression in Class II PAH

Publish date: November 1, 2007
PDF Download

 

The study results support the benefit of treating patients withless-severe PAH. DR. RUBIN

Pages

Recommended Reading

Homocysteine-Lowering Therapy: Doubts Persist
MDedge Internal Medicine
Asymptomatic PAD Linked With High Mortality
MDedge Internal Medicine
Thrombolysis for DVT Tied to Sevenfold Rise in Mortality
MDedge Internal Medicine
Aggressive Revascularization in ACS Fails Women
MDedge Internal Medicine
Laparoscopic Bypass Offers Advantages
MDedge Internal Medicine
Outcomes 'Terrible' After Stent Thrombosis
MDedge Internal Medicine
Pioglitazone May Lower Risk of MI, Stroke
MDedge Internal Medicine
Noncardiac Surgery Not Riskier in Heart Patients
MDedge Internal Medicine
CT May Be Used to Assess Myocardial Ischemia
MDedge Internal Medicine
Oral Contraceptive Use Linked to Arterial Plaque
MDedge Internal Medicine